Cefadroxil-d4 hydrate

For research use only. Not for therapeutic Use.

  • CAT Number: S000262
  • CAS Number: 1426174-38-0
  • Molecular Formula: C16H15D4N3O6S
  • Molecular Weight: 385.43
  • Purity: ≥95%
Inquiry Now

Cefadroxil-d4 hydrate (CAS: 1426174-38-0), a premium pharmaceutical research compound designed for advanced antibacterial studies. As a deuterated analog of Cefadroxil, it offers enhanced stability and improved pharmacokinetic properties. Cefadroxil-d4 hydrate is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel antibacterial therapies. Trusted by leading laboratories, Cefadroxil-d4 hydrate is your go-to solution for cutting-edge antibacterial research. Unlock new possibilities in infection treatment with Cefadroxil-d4 hydrate, where innovation meets reliability.


Catalog Number S000262
CAS Number 1426174-38-0
Molecular Formula C16H15D4N3O6S
Purity ≥95%
IUPAC Name (6R,7R)-7-[[(2R)-2-amino-2-(2,3,5,6-tetradeuterio-4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate
InChI InChI=1S/C16H17N3O5S.H2O/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8;/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24);1H2/t10-,11-,15-;/m1./s1/i2D,3D,4D,5D;
InChIKey NBFNMSULHIODTC-AUTKPGNWSA-N
SMILES [2H]C1=C(C(=C(C(=C1[C@H](C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(=O)O)N)[2H])[2H])O)[2H].O
Reference

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[Content Brief]

[2]. Chen X, et al. Influence of peptide transporter 2 (PEPT2) on the distribution of cefadroxil in mouse brain: A microdialysis study. Biochem Pharmacol. 2017 May 1;131:89-97.
[Content Brief]

[3]. Hu Y, et al. Species differences in the pharmacokinetics of cefadroxil as determined in wildtype and humanized PepT1 mice. Biochem Pharmacol. 2016 May 1;107:81-90.
[Content Brief]

Request a Quote